Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3020523 | 0.78 | KMT2A (0.41) | TDO2KMT2AALDH1A1PDK1PDK2 | |
| SCHEMBL2821006 | 0.73 | KMT2A (0.47) | TDO2KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL2821721 | 0.72 | KMT2A (0.51) | KMT2AALDH1A1IDH1BRD4BRD2 | |
| SCHEMBL2818870 | 0.72 | ALDH1A1 (0.46) | KMT2AALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL2821673 | 0.71 | KMT2A (0.54) | KMT2AALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL2821764 | 0.71 | PKM (0.57) | KMT2AALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL2823333 | 0.71 | ALDH1A1 (0.59) | KMT2AALDH1A1BRD4BRD2BRD3 | |
| SCHEMBL2822066 | 0.70 | KMT2A (0.44) | KMT2AALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL2820403 | 0.70 | KMT2A (0.54) | KMT2AALDH1A1PDK2BRD4BRD2 | |
| SCHEMBL2821664 | 0.70 | ALDH1A1 (0.49) | KMT2AALDH1A1BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242118-B2 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7700586-B2 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20050070582-A1 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | BAYER HEALTHCARE AG (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | CCR3, CCR1, CCR2 | TDO2 2053/4885KMT2A 2753/4885ALDH1A1 2416/4885 |
| US-20050070582-A1 | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | CCR3, CCR1, CCR2 | TDO2 2053/4885KMT2A 2753/4885ALDH1A1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.